Skip to main content
Orphan Drug designation granted to BioXcel's AML drug candidate

The FDA granted orphan drug status to BioXcel Therapeutics' immuno-oncology drug BXCL701 as a treatment for acute myeloid leukemia. The drug is also being developed to treat a rare type of prostate cancer and pancreatic cancer.

Full Story: